Peptides for Longevity
Research overview of peptides studied for longevity, healthspan, and lifespan extension. Epithalon, MOTS-c, humanin, and longevity peptide evidence.
Research Overview
Longevity peptide research represents one of the most challenging areas to validate, as lifespan studies require decades in humans. Most evidence comes from animal models, cellular studies, and surrogate biomarkers of aging rather than direct longevity measurements.
Epithalon and the Khavinson bioregulators originate from the St. Petersburg Institute of Bioregulation and Gerontology, with reported effects on telomerase activation and organ-specific aging. While intriguing, most research appears in Russian/CIS literature with limited Western replication.
Mitochondrial-derived peptides (MOTS-c, humanin, SHLPs) represent an emerging field linking mitochondrial function to aging processes. These endogenously produced peptides may mediate some effects of metabolic interventions on healthspan, though therapeutic applications remain investigational.
Key Longevity Peptides
Epithalon (Epitalon)
Status: Not approved; research compound
| Research Area | Evidence Level |
|---|---|
| Telomerase activation | Low (cell studies) |
| Animal lifespan | Low (limited studies) |
| Human longevity | Very Low |
Primary research from Khavinson laboratory; limited independent replication.
MOTS-c
Status: Endogenous; research stage
| Research Area | Evidence Level |
|---|---|
| Metabolic regulation | Low-Moderate |
| Exercise mimetic | Low (preclinical) |
| Aging biomarkers | Low |
Mitochondrial-derived peptide with emerging research on metabolic aging.
Humanin
Status: Endogenous; research stage
| Research Area | Evidence Level |
|---|---|
| Neuroprotection | Low-Moderate |
| Metabolic effects | Low |
| Aging association | Low |
Correlational studies link humanin levels to longevity; causation unclear.
Bioregulators (Khavinson Peptides)
| Category | Example Peptides | Evidence |
|---|---|---|
| Thymic | Thymalin, Thymogen | Low-Moderate (Russia) |
| Pineal | Epithalon, Pinealon | Low |
| Other organ | Various | Very Low |
Evidence Challenges in Longevity Research
- Timeframe: Human lifespan studies take decades
- Surrogate markers: Telomere length, biomarkers may not predict longevity
- Species translation: Animal lifespans don’t directly predict human effects
- Publication bias: Positive results overrepresented
Proxy Endpoints Used
| Endpoint | Relevance to Longevity |
|---|---|
| Telomere length | Uncertain correlation |
| Telomerase activity | Mechanism, not outcome |
| Aging biomarkers | Surrogate, unvalidated |
| Healthspan metrics | More relevant, harder to measure |
Research Limitations
- Most longevity peptide claims exceed evidence
- No peptide has demonstrated human lifespan extension
- Bioregulator literature concentrated in single research network
- Western replication studies largely absent
- Regulatory approval status reflects evidence gaps
Honest Assessment
No peptide has been shown to extend human lifespan. Research on healthspan effects is more tractable but still limited. Claims should be evaluated against direct evidence, not theoretical mechanisms.
Peptides Studied for Longevity
Humanin
ModerateA 24-amino acid mitochondria-derived peptide (MDP) discovered in 2001 that shows cytoprotective, anti-apoptotic, and neuroprotective effects in preclinical studies. Represents a novel class of signaling molecules encoded within mitochondrial DNA. Extensive academic research with emerging interest in aging, metabolic disease, and neurodegeneration, but no approved clinical applications.
Epithalon
LowA synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan. 2025 independent Western research confirmed telomerase activation in vitro. Still not approved anywhere; no controlled human clinical trials.
MOTS-c
LowA 16-amino acid mitochondrial-derived peptide encoded in mtDNA that targets AMPK/mTOR pathways for metabolic regulation. Preclinical studies show exercise mimetic and geroprotective effects. Lower MOTS-c levels found in T2D patients. No clinical trials yet conducted in humans.
FOXO4-DRI
Very LowA D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, selectively eliminating senescent cells (senolytic). Preclinical studies in aged mice demonstrated restored fitness, fur density, and renal function. No human clinical trials conducted. More selective than BCL-2 inhibitors but remains unproven in humans.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.